Tin tức & Cập nhật

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024 bởiSarah Cheung

Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.

 

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024
Rectal spacers in MR-guided SBRT for localized prostate cancer very well tolerated, improve rectal sparing and target coverag
Rectal spacers in MR-guided SBRT for localized prostate cancer very well tolerated, improve rectal sparing and target coverage
20 Mar 2024
Men with HR+ breast cancer have high breast cancer─specific mortality risk at 20 years
Men with HR+ breast cancer have high breast cancer─specific mortality risk at 20 years
13 Mar 2024